Literature DB >> 15756503

[Changes for rheumatology in the G-DRG system 2005].

W Fiori1, N Roeder, H-J Lakomek, W Liman, N Köneke, J L Hülsemann, H Lehmann, A Wenke.   

Abstract

The German prospective payment system G-DRG has been recently adapted and recalculated. Apart from the adjustments of the G-DRG classification system itself changes in the legal framework like the extension of the "convergence period" or the limitation of budget loss due to DRG introduction have to be considered. Especially the introduction of new procedure codes (OPS) describing the specialized and complex rheumatologic treatment of inpatients might be of significant importance. Even though these procedures will not yet develop influence on the grouping process in 2005, it will enable a more accurate description of the efforts of acute-rheumatologic treatment which can be used for further adaptations of the DRG algorithm. Numerous newly introduced additive payment components (ZE) result in a more adequate description of the "DRG-products". Although not increasing the individual hospital budget, these additive payments contribute to more transparency of high cost services and can be addressed separately from the DRG-budget. Furthermore a lot of other relevant changes to the G-DRG catalogue, the classification systems ICD-10-GM and OPS-301 and the German Coding Standards (DKR) are presented.

Entities:  

Mesh:

Year:  2005        PMID: 15756503     DOI: 10.1007/s00393-005-0702-z

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  4 in total

1.  [The multimodal rheumatologic complex treatment (OPS 8-983)--challenges, solutions and perspectives].

Authors:  H-J Lakomek; W Fiori; K Buscham; J L Hülsemann; N Köneke; W Liman; E Märker-Hermann; N Roeder
Journal:  Z Rheumatol       Date:  2005-11       Impact factor: 1.372

2.  [What changes for rheumatologists in the G-DRG system 2006?].

Authors:  A Liedtke-Dyong; W Fiori; H-J Lakomek; J L Hülsemann; N Köneke; W Liman; N Roeder
Journal:  Z Rheumatol       Date:  2006-07       Impact factor: 1.372

Review 3.  [Treat-to-target (T2T) from the perspective of inpatient rheumatology].

Authors:  H-J Lakomek; A Krause
Journal:  Z Rheumatol       Date:  2011-10       Impact factor: 1.372

Review 4.  [Structures of acute rheumatic care].

Authors:  M Stier-Jarmer; W Liman; G Stucki; J Braun
Journal:  Z Rheumatol       Date:  2006-12       Impact factor: 1.372

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.